To address the growing opportunity for products using novel drug delivery systems, Lupin is leveraging its expertise in complex
finished products, development and manufacturing.
The focus of Lupin's NDDS is on:
Oral controlled release systems (OCRS)
- High dose/frequency/pill burden drugs
- Patentable platform/product specific technologies
Advance drug delivery systems (ADDS)
- Invasive to non-invasive DDS (injectable to oral)
- Pulmonary DDS
A
proof of Lupin's NDDS capability:
the world's first once-a-day
cephalexin tablet (Ceff-ER) launched in May
2003 and the world's first once-a-day
cefadroxil tablet (Odoxil OD) launched in
November 2003
Seven
patent applications for NDDS platforms
in major areas
